A simplified, non-invasive fecal-based DNA integrity assay and iFOBT for colorectal cancer detection

  • Murugan Kalimutho
  • Giovanna Del Vecchio Blanco
  • Micaela Cretella
  • Elena Mannisi
  • Pierpaolo Sileri
  • Amanda Formosa
  • Francesco Pallone
  • Giorgio Federici
  • Sergio Bernardini
Original Article

Abstract

Purpose

Neoplasia cells exfoliated from colorectal epithelium have dysfunctional apoptotic mechanisms, thus it is possible to identify high-molecular weight DNA fragments in feces. This prospective single-center study was performed to evaluate the sensitivity and specificity of fecal-based DNA integrity versus immunological fecal occult blood test (iFOBT) and calprotectin for colorectal cancer (CRC) and adenoma detection.

Methods

Feces were collected from 204 subjects and DNA integrity was quantified by quantitative-denaturing high performance liquid chromatography (QdHPLC). Calprotectin and iFOBT were assessed using commercial kits. The diagnostic performance was calculated by receiver operating characteristic (ROC) curves analysis.

Results

A total of 192 fecal specimens were analyzed and 12 samples were excluded due to DNA degradation. We found long DNA (L-DNA) occurrence in feces with a sensitivity of 86% (n = 24/28) and a specificity of 81% for CRC detection. To minimize false-positive cases of the developed test, area under the curve of ROC was evaluated such that the specificity was increased to 92% with decreased sensitivity to 79%, p = 0.0001 for CRC detection. iFOBT was positive in 51% (n = 14/27) while calprotectin was positive in 75% (n = 18/27). The combination of iFOBT and L-DNA identified a greater number of CRC cases with a sensitivity of 89% and a specificity of 95%, p < 0.001. The combination also improved the sensitivity of polyps, particularly high-grade dysplasia and advanced adenoma (33%, p = 0.0015) as opposed to a single evaluation assay (17–21%).

Conclusions

This study illustrates the usefulness of fecal DNA integrity assay by QdHPLC as a non-invasive, easy-to-perform, and reproducible method with a high level of sensitivity in detecting individuals with colorectal neoplasia. Combination of iFOBT and L-DNA improves the sensitivity for CRC and adenoma detection.

Keywords

CRC DIA Feces iFOBT L-DNA QdHPLC-DIA 

Abbreviations

CRC

Colorectal cancer

FOBT

Fecal occult blood test

gFOBT

Guaic FOBT

iFOBT

Immunochemical FOBT

fDNA

Fecal DNA

DIA

DNA integrity assay

L-DNA

Long DNA

QdHPLC

Quantitative denaturing high performance liquid chromatography

AVG-DIA

Average DIA

ROC

Receiver operating characteristic

Notes

Acknowledgment

This work was supported by grants from the University Hospital Tor Vergata, University of Rome. MK was supported by the pre-doctoral scholarship for foreign student under the International Italian Government University scholarship. We thank Paolo Zaccagna from Transgenomic Inc. for his invaluable suggestions, comments, as well as technical support on the QdHPLC application.

Conflict of interest

The authors state that there are no conflicts of interest regarding the publication of this article. Support provided by Transgenomic Inc. played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

Supplementary material

384_2010_1128_MOESM1_ESM.xls (21 kb)
Table S1 Demographic and clinical characteristic of CRC patients together with the ratio of long DNA by Q-dHPLC, iFOBT, and calprotection results (XLS 21 kb).

References

  1. 1.
    Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E et al (2004) Cancer statistics. CA Cancer J Clin 54:8–29PubMedCrossRefGoogle Scholar
  2. 2.
    Zavoral M, Suchanek S, Zavada F, Dusek L, Muzik J, Seifert B, Fric P (2009) Colorectal cancer screening in Europe. World J Gastroenterol 21:5907–5915CrossRefGoogle Scholar
  3. 3.
    Walsh JM, Terdiman JP (2003) Colorectal cancer screening: scientific review. JAMA 289:1288–1296PubMedCrossRefGoogle Scholar
  4. 4.
    Mandel JS, Church TR, Ederer F, Bond JH (1999) Colorectal cancer mortality: effectiveness of biennal screening for fecal occult blood. J Natl Cancer Inst 91:434–437PubMedCrossRefGoogle Scholar
  5. 5.
    Mande JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, Ederer F, The Minnesota Colon Cancer Control Study (1993) Reducing mortality from colorectal cancer by screening for faecal occult blood. N Engl J Med 328(19):1365–71CrossRefGoogle Scholar
  6. 6.
    Ahlquist D, Shuber AP (2002) Stool screening for colorectal cancer: evolution from occult blood to molecular markers. Clin Chim Acta 315:157–168PubMedCrossRefGoogle Scholar
  7. 7.
    Cole SR, Young GP (1999) Dietary restriction impairs compliance with FOB screening for colorectal cancer. Gastroenterology 116:A391Google Scholar
  8. 8.
    Ahlquist DA, McGill DB, Fleming JL, Schwartz S, Wieand HS, Rubin J, Moertel CG (1089) Patterns of occult bleeding in asymptomatic colorectal cancer. Cancer 63:1826–1830CrossRefGoogle Scholar
  9. 9.
    Guittet L, Bouvier V, Mariotte N, Vallee JP, Arsène D, Boutreux S et al (2007) Comparison of a guaiac based and an immunochemical faecal occult blood test in screening for colorectal cancer in a general average risk population. Gut 56:210–214PubMedCrossRefGoogle Scholar
  10. 10.
    Levi Z, Rozen P, Hazazi R, Vilkin A, Waked A, Maoz E et al (2007) A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med 146:244–255PubMedGoogle Scholar
  11. 11.
    Levi Z, Hazazi R, Rozen P, Vilkin A, Waked A, Niv Y (2006) A quantitative immunochemical faecal occult blood test is more efficient for detecting significant colorectal neoplasia than a sensitive guaiac test. Aliment Pharmacol Ther 23:1359–1364PubMedCrossRefGoogle Scholar
  12. 12.
    Limburg PJ, Devens ME, Harrington JJ, Diehl NN, Mahoney DW, Ahlquist DA (2003) Prospective evaluation of fecal calprotectin as a screening biomarker for colorectal neoplasia. AMJ Gastroenterol 98:2299–2305CrossRefGoogle Scholar
  13. 13.
    Kronborg O, Ugstad M, Fuglerud P, Johne B, Hardcastle J, Scholefield JH et al (2000) Faecal calprotectin levels in a high risk population for colorectal neoplasia. Gut 46:795–800PubMedCrossRefGoogle Scholar
  14. 14.
    Tibble J, Sigthorsson G, Foster R, Sherwood R, Fagerhol M, Bjarnason I (2001) Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut 49:402–408PubMedCrossRefGoogle Scholar
  15. 15.
    Hoff G, Grotmol T, Thiis-Evensen E, Bretthauer M, Gondal G, Vatn MH (2004) Testing for faecal calprotectin (PhiCal) in the Norwegian colorectal cancer prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT). Gut 53:1329–1333PubMedCrossRefGoogle Scholar
  16. 16.
    Røseth AG, Fagerhol MK, Aadland E, Schjønsby H (1992) Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 27:793–798PubMedCrossRefGoogle Scholar
  17. 17.
    Sidransky D, Tokino T, Hamilton SR, Kinzler KW, Levin B, Frost P, Vogelstein B (1992) Identification of ras oncogene mutations in the stool of patient with curable colorectal tumors. Science 256:102–105PubMedCrossRefGoogle Scholar
  18. 18.
    Traverso G, Shuber A, Levin B, Johnson C, Olsson L, Schoetz DJ (2002) Detection of APC mutations in fecal DNA from patients with colorectal tumors. N Engl J Med 346:311–320PubMedCrossRefGoogle Scholar
  19. 19.
    Bedi A, Pasricha PJ, Akhtar AJ, BarberJP BGC, Giardiello FM et al (1995) Inhibition of apoptosis during developments of colorectal cancer. Cancer Res 55:1811–1816PubMedGoogle Scholar
  20. 20.
    Ahlquist DA, Skoletsky JE, Boynton KA, Harrington JJ, Mahoney DW, Pierceall WE et al (2000) Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 119:1219–1227PubMedCrossRefGoogle Scholar
  21. 21.
    Boynton KA, Summerhayes IC, Ahlquist DA, Shuber AP (2003) DNA integrity as a potential marker for stool-based detection of colorectal cancer. Clin Chem 49:1058–1065PubMedCrossRefGoogle Scholar
  22. 22.
    Kalimutho M, Blanco GD, Gravina P, Cretella M, Mannucci L, Mannisi E et al (2010) Quantitative Denaturing high performance liquid chromatography (dHPLC) detection of APC Long DNA and mutations in faeces from colorectal cancer patients. Clin Chem Lab Med 48(9):1303–1311Google Scholar
  23. 23.
    Abbaszadegan MR, Tavasoli A, Velayati A, Sima HR, Vosooghinia H, Farzadnia M et al (2007) Stool-based DNA testing a new non invasive method for colorectal cancer screening, the first report from Iran. World J Gastroenterol 13:1528–1533PubMedGoogle Scholar
  24. 24.
    Itzkowitz S, Brand R, Jandorf L, Durkee K, Millholland J, Rabeneck L et al (2008) A simplified, noninvasive stool DNA test for colorectal cancer detection. Am J Gastroenterol 103:2862–2870PubMedCrossRefGoogle Scholar
  25. 25.
    Kim Y, Lee S, Park S, Jeon H, Lee W, Kim JK et al (2003) Gastrointestinal tract cancer screening using fecal carcinoembryonic antigen. Ann Clin Lab Sci 33:32–38PubMedGoogle Scholar
  26. 26.
    Pucci S, Bonanno E, Sesti F, Mazzarelli P, Mauriello A, Ricci F et al (2009) Clusterin in stool: a new biomarker for colon cancer screening? Am J Gastroenterol 104:2807–2815PubMedCrossRefGoogle Scholar
  27. 27.
    Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME, Colorectal Cancer Study Group (2004) Fecal DNA versus fecal occult blood for colorectal cancer screening in an average-risk population. N Engl J Med 351:2704–2714PubMedCrossRefGoogle Scholar
  28. 28.
    Booth A (2007) Minimally invasive biomarkers for detection and staging of colorectal cancer. Cancer Lett 249:87–96PubMedCrossRefGoogle Scholar
  29. 29.
    Loktionov A, O’Neill IK, Silvester KR, Cummings JH, Middleton SJ, Miller R (1998) Quantitation of DNA from exfoliated colonocytes isolated from human stool surface as a novel noninvasive screening test for colorectal cancer. Clin Cancer Res 4:337–342PubMedGoogle Scholar
  30. 30.
    Ouyang DL, Chen JJ, Getzenberg RH, Schoen RE (2005) Non invasive testing for colorectal cancer. A review. J Gastroenterol 100:1393–1403Google Scholar
  31. 31.
    Røseth AG, Kristinsson J, Fagerhol MK, Schjønsby H, Aadland E, Nygaard K, Roald B (1993) Faecal calprotectin: a novel test for the diagnosis of colorectal cancer? Scand J Gastroenterol 28:1073–1076PubMedCrossRefGoogle Scholar
  32. 32.
    Zou H, Taylor WR, Harrington JJ, Hussain FT, Cao X, Loprinzi CL et al (2009) High detection rates of colorectal neoplasia by stool DNA testing with a novel digital melt curve assay. Gastroenterology 136:459–470PubMedCrossRefGoogle Scholar
  33. 33.
    Lai LP, Su YN, Hsieh FJ, Chiang FT, Juang JM, Liu YB et al (2005) Denaturing high-performance liquid chromatography screening of the long QT syndrome-related cardiac sodium and potassium channel genes and identification of novel mutations and single nucleotide polymorphisms. J Hum Genet 50:490–496PubMedCrossRefGoogle Scholar
  34. 34.
    Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61:759–767PubMedCrossRefGoogle Scholar
  35. 35.
    Calistri D, Rengucci C, Lattuneddu A, Francioni G, Polifemo AM, Nanni O et al (2004) Detection of colorectal cancer by a quantitative fluorescence determination of DNA amplification in stool. Neoplasia 6:536–540PubMedCrossRefGoogle Scholar
  36. 36.
    DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44:837–845PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Murugan Kalimutho
    • 1
    • 4
  • Giovanna Del Vecchio Blanco
    • 1
    • 3
  • Micaela Cretella
    • 3
  • Elena Mannisi
    • 3
  • Pierpaolo Sileri
    • 3
  • Amanda Formosa
    • 1
  • Francesco Pallone
    • 1
    • 3
  • Giorgio Federici
    • 1
    • 2
  • Sergio Bernardini
    • 1
    • 2
  1. 1.Department of Internal MedicineUniversity of Rome “Tor Vergata”RomeItaly
  2. 2.Department of Laboratory Medicine,“U.O.C. Clinical Molecular Biology and Biochemistry”University Hospital Tor VergataRomeItaly
  3. 3.Gastroenterology UnitUniversity Hospital Tor VergataRomeItaly
  4. 4.Centre for Cancer Research and Cell Biology (CCRCB)Queen’s UniversityBelfastUK

Personalised recommendations